Table 2.
Modified miRNAs in SCC.
| Nr | Ref | Expression | miRNA | Probe | Species | Role |
|---|---|---|---|---|---|---|
| 1 | Sand M. et al. [51] | upregulated | miRNA-31 | tissue | human | downregulate the tumor suppressor RhoBTB1 (Rho Related BTB Domain Containing 1) in the cSCC cell line A-431, determing cell proliferation and invasion |
| miRNA-135b | miRNA-135b can regulate cell migration and tumor invasiveness in early stages of SCC progression and can act as an oncogenic miRNA in human keratinocytes | |||||
| miRNA-424 | determines angiogenesis, regulates cell-autonomous angiogenic functions | |||||
| miRNA-21* miRNA-374a miRNA-196a |
not mentioned | |||||
| miRNA-18a | associated with the Sonic Hedgehog pathway, correlated with molecular pathogenesis of cSCC | |||||
| miRNA-766 miRNA-128 |
not mentioned | |||||
| miRNA-130b | downregulate the tumor suppressor protein 53-induced nuclear protein 1 (TP53INP1) | |||||
| miRNA-455-5p | not mentioned | |||||
| miRNA-21 | targets phosphatase and tensin homolog (PTEN), PDC4 (Programed Cell Death 4) and BTG2 (B-cell translocation gene 2) | |||||
| downregulated | miRNA-30a* miRNA-133b miRNA-101 miRNA-4324 miRNA-136 |
not mentioned | ||||
| miRNA-378 | targets insulin-like growth factor 1 receptor (IGF1R) and caspase 3; reduced expression in basal cell carcinoma | |||||
| miRNA-204 miRNA-497 miRNA-29c miRNA-214 |
not mentioned | |||||
| miRNA-145 | inhibits actin-binding protein Fascin homolog 1 (FSCN1) in esophageal squamous cell carcinoma; down-regulated in basal cell carcinoma | |||||
| miRNA-199a-5p miRNA-125b |
not mentioned | |||||
| miRNA-140-3p | targets CD38; down-regulated in basal cell carcinoma | |||||
| miRNA-26a | downregulation of oncogene Histone-lysine N-methyltransferase (EZH2) | |||||
| 2 | P Dziunycz et al. [52] | upregulated | miRNA-21 | tissue | human | essential role in the development or maintenance of SCC of the skin |
| miRNA-184 miRNA-205 |
not mentioned | |||||
| downregulated | miRNA-203 | unleash p63 expression, leading to decreased cell senescence and supporting SCC formation | ||||
| miRNA-378 | not mentioned | |||||
| 3 | Yamane et al. [53] | downregulated | miRNA-124 miRNA-214 |
Tissue and serum | human | lead to overexpression of ERK1/2. May lead to the development of useful biomarkers for early detection of this tumor and to new treatments using miRNA |
| 4 | Zhang L et al. [56] | downregulated | miRNA-20a | tissue | human | might play important roles in the tumorigenesis and progression of CSCC patients, may serve as a novel molecular marker to predict the tumor progression and inferior prognosis of CSCC patients |
| 5 | Gong et al. [57] | upregulated | miRNA-221 | blood | human | significantly promotes cell proliferation |
| 6 | Kanitz et al. [64] | downregulated | miRNA-361-5p | tissue | human | regulator of VEGFA expression |
| 7 | Chen et al. [65] | downregulated | miRNA-346 | tissue | human | promotes the cSCC cell proliferation and migration through directly targeting SRCIN1 (SRC Kinase Signaling Inhibitor 1). This study may provide a new therapeutic target for cSCC. |
| 8 | Xu et al. [66] | downregulated | miRNA-125b | tissue | human | potential therapeutic biomarker. Matrix metalloproteinase (MMP)13 was considered a direct target of miRNA-125b |
| 9 | Olasz et al. [67] | upregulated | miRNA-135b | tissue | human | miRNA-135b can regulate cell migration and tumor invasiveness in early stages of SCC progression and can act as an oncogenic miRNA in human keratinocytes |
| 9 | Zhou M et al. [68] | upregulated | miRNA-365 | tissue | human | downregulates NFIB (nuclear Factor I B) and inhibits the expression of cyclin-dependent kinase CDK6 and CDK4 |